Market News & Trends
Avantor Names New President & CEO
Avantor Performance Materials recently announced the appointment of John M. Steitz as President and Chief Executive Officer. Mr. Steitz assumes these roles from Avantor Chairman…
New Findings Advance Industry Understanding of Standardizing In Vitro Tests for Lipid-Based Formulations
With the push to bring new drugs to market faster, the healthcare industry has made significant advances in utilizing lipid-based drug delivery systems to expedite…
Regulus Therapeutics Files for Multi-Million IPO
Regulus Therapeutics Inc., a biopharmaceutical company founded by Alnylam Pharmaceuticals and Isis Pharmaceuticals, recently announced it has filed a registration statement on Form S-1 with…
TG Therapeutics; Rhizen Pharmaceuticals Ink $250-Million Agreement
TG Therapeutics, Inc. and Rhizen Pharmaceuticals SA recently announced the companies have entered into an exclusive global agreement to collaborate on the development and commercialization…
The Wistar Institute of Philadelphia Signs Agreement With DavosPharma
DavosPharma recently announced it has signed a collaborative agreement with The Wistar Institute of Philadelphia. This agreement provides DMPK, and preclinical IND enabling studies and…
United Drug Acquires Leading Clinical Trials Materials Business
United Drug plc recently announced it has reached an agreement to acquire the UK and US clinical services businesses (combined Bilcare Global Clinical Supplies or…
GeNO LLC Receives Two Additional Patents for Inhaled Drug Delivery
GeNO LLC recently announced it has been awarded two new US patents on its proprietary nitric oxide (NO) generation and delivery technology. This brings to…
Oculus Innovative Sciences Announces Licensing Agreement
Oculus Innovative Sciences, Inc. recently announced the exclusive licensing of the company's Microcyn-based human healthcare products in Mexico, South/Central America, and the Caribbean to More…
Protalix BioTherapeutics Receives Clearance to Initiate Study
Protalix BioTherapeutics, Inc. recently announced it has received clearance of its IND application from the US FDA to initiate clinical trials of PRX-102. The company…
Quintiles Acquires Company to Advance Personalized Medicine
Quintiles recently announced the acquisition of Expression Analysis, Inc. (EA), a premier provider of genomics testing and analysis to biopharma, academic, government, and non-profit customers,…
Theorem Clinical Research & Gallus BioPharmaceuticals Announce Exclusive Partnership
Theorem Clinical Research has entered an exclusive partnership with Gallus BioPharmaceuticals in which Gallus will provide process development and clinical and commercial supply for mammalian…
8/15/2012
Quintiles Acquires Company to Advance Personalized Medicine Quintiles recently announced the acquisition of Expression Analysis, Inc. (EA), a premier provider of genomics testing and analysis…
8/8/2012
Researchers Discover New Mechanism Behind Resistance to Cancer Treatment Developing resistance to chemotherapy is a nearly universal, ultimately lethal consequence for cancer patients with solid…
Advantar Adds Executive Superhero
Advantar Laboratories, Inc. recently announced the addition of Dave Bergstrom, PhD, to the company's executive team as Chief Operating Officer. Dr. Bergstrom will be responsible…
Aptar's Dose Indicator Chosen for Allergic Rhinitis
ZETONNA (ciclesonide) Nasal Aerosol from Sunovion Pharmaceuticals Inc., equipped with an Aptar Pharma Landmark® dose indicator, is now available in the US for the treatment…
CoreRx, Inc. Opens State-of-the-Art Facility
CoreRx, Inc. recently announced it is now occupying its new 35,000-sq-ft facility in Clearwater, FL. This distinct facility will enable CoreRx's scientific staff to custom…
InSite Vision Initiates First Phase III Clinical Study
InSite Vision Incorporated recently announced that patient enrollment has begun in the first Phase III clinical trial of BromSite (ISV-303) for the reduction of pain…
Purac Acquires FiberLive Technology
Purac recently announced it has acquired the FiberLive technology from Vivoxid Ltd., Finland. The acquisition includes the intellectual property of the FiberLive technology and its…
Researchers Discover New Mechanism Behind Resistance to Cancer Treatment
Developing resistance to chemotherapy is a nearly universal, ultimately lethal consequence for cancer patients with solid tumors - such as those of the breast, prostate,…
Caisson Biotech Appoints New CEO & President
Caisson Biotech, L.L.C. recently announced it has appointed Glenn E. Nedwin, PhD, as Chief Executive Officer and President. Former Caisson CEO, Thomas Harlan, who is…
